Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMarlowe Regulatory News (MRL)

  • This share is currently suspended. It was suspended at a price of 440.00
  • There is currently no data for MRL

Additional Share Buyback Programme

28 Apr 2025 07:05

RNS Number : 2988G
Marlowe PLC
28 April 2025
 

28 April 2025

Marlowe plc

("Marlowe", the "Company" or the "Group")

Additional Share Buyback Programme

 

Marlowe, the leader in business-critical services, is pleased to announce that it has now returned an aggregate of £72 million to Group shareholders pursuant to the share buyback programme announced by the Company on 22 May 2024 to return up to £75 million (the "Programme").

 

The Group announces that on conclusion of the Programme it intends to return up to an additional £15 million to shareholders by way of on-market purchases of ordinary shares of 50 pence each in the capital of the Company ("Ordinary Shares") from the date of this announcement (the "Additional Programme").

 

The Additional Programme will be undertaken on the same terms as the Programme, will be funded from the Company's existing cash resources, and will operate under the authorities granted by shareholders at the Group's General Meeting ("GM") held on 20 February 2025.

 

Pursuant to the buyback authority granted at the GM, the maximum price which may be paid by the Company per Ordinary Share pursuant to the Additional Programme shall not be more than 5 per cent above the average middle market quotations for an Ordinary Share (as derived from the London Stock Exchange AIM All-Share List) for the five business days immediately preceding the date on which such share is contracted to be purchased.

 

The Company has appointed Cavendish Capital Markets Limited ("Cavendish") to manage the Additional Programme on its behalf and to independently carry out on-market purchases of its Ordinary Shares. Share purchases will take place in open market transactions and may be made from time to time depending on market conditions, share price, trading volume and other factors. The Company is not in a close period and currently has no unpublished price sensitive information.

 

The Additional Programme will be effective on conclusion of the Programme and will, unless terminated at an earlier date, expire on the earlier of the completion of the Additional Programme or at the conclusion of the Company's 2025 Annual General Meeting ("Expiry Date").

 

Marlowe intends to cancel all of the repurchased Ordinary Shares. Purchases may continue during any closed period to which the Company is subject to from the date of this announcement to the Expiry Date and any market purchase of Ordinary Shares pursuant to the Extension are expected to be announced no later than 7.30am on the business day following the day on which the purchase occurred.

 

The Company has determined that it will not rely on the safe harbour conditions for trading set out in Article 3(2) and Article 3(3) of the Commission Delegated Regulation (EU) 2016/1052 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018) given the limited liquidity in the Ordinary Shares and limitations that the conditions would impose on the number of Ordinary Shares that can be purchased and, as such, the Company may (a) purchase Ordinary Shares at a price higher than the higher of the price of the last independent trade and the highest current independent bid for an Ordinary Share, and (b) purchase on any trading day materially in excess of 25 per cent of the average daily volume in the 20 trading days preceding the date on which the purchase is carried out.

 

As at 24 April 2025 the Company's total issued share capital consisted of 78,518,814 Ordinary Shares, with one voting right per share. As at this date the Group did not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Group is 78,518,814.

 

 

For further information:

 

 

 

Marlowe plc

Lord Ashcroft, Interim Non-Executive Chair

Adam Councell, Chief Financial Officer

Benjamin Tucker, Head of Group Reporting

 

 

www.marloweplc.com

Tel: +44 (0)20 3813 8498

IR@marloweplc.com

 

Cavendish Capital Markets Limited (Nominated Adviser & Broker)

Ben Jeynes

George Lawson

Tel: +44 (0)20 7220 0500

FTI Consulting

Nick Hasell

Alex Le May

Tel: +44 (0)20 3727 1340

 

About Marlowe plc

Marlowe is a leader in business-critical services which ensures compliance with strict regulations and insurance requirements across Fire Safety & Security and Water & Air Hygiene. The Group has a national footprint and serves approximately 27,000 customers across office complexes, high streets & leisure facilities, manufacturing plants and industrial estates, and include thousands of SMEs, local authorities, facilities management providers, multi-site NHS trusts and FTSE 100 companies.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEELFLEZLXBBZ
Date   Source Headline
13th Sep 20237:00 amRNSAnnual General Meeting and Trading Update
4th Sep 20237:00 amRNSHolding(s) in Company
8th Aug 20237:00 amRNSExercise of Share Options and Total Voting Rights
7th Aug 20237:45 amRNSResponse to Speculation
4th Aug 20233:50 pmRNSHolding(s) in Company
3rd Aug 20235:25 pmRNSHolding(s) in Company
31st Jul 20233:30 pmRNSIssue of Equity and Total Voting Rights
26th Jul 20237:00 amRNSAcquisition of IMSM
18th Jul 202312:15 pmRNSCapital Reduction Effective
13th Jul 20232:00 pmRNSPublication of Notice of AGM and Annual Report
29th Jun 20237:00 amRNSPreliminary results
26th Jun 20237:00 amRNSNotice of Full Year Results
23rd Jun 20234:56 pmRNSHolding(s) in Company
19th Jun 202311:06 amRNSResult of General Meeting
5th Jun 20239:31 amRNSHolding(s) in Company
2nd Jun 20232:51 pmRNSPosting of Circular and Notice of General Meeting
2nd Jun 202312:36 pmRNSHolding(s) in Company
18th Apr 20231:45 pmRNSHolding(s) in Company
29th Mar 20237:00 amRNSCapital Markets Day Replay
28th Mar 20237:00 amRNSCapital Markets Day and Trading Update
7th Mar 20237:00 amRNSNotice of Capital Markets Event
28th Feb 20232:20 pmRNSHolding(s) in Company
26th Jan 20231:46 pmRNSHolding(s) in Company
5th Jan 20237:00 amRNSNotice of Capital Markets Event
2nd Dec 20229:00 amRNSNotice of Investor Presentation
1st Dec 202210:34 amRNSDirector/PDMR Shareholding
1st Dec 20229:00 amRNSDirector/PDMR Shareholding
24th Nov 20222:14 pmRNSDirector/PDMR Shareholding
24th Nov 20221:48 pmRNSDirector/PDMR Shareholding
23rd Nov 20227:00 amRNSHalf-year Report
21st Nov 202212:54 pmRNSExercise of Share Options and Total Voting Rights
17th Nov 20227:00 amRNSNotice of Interim Results
2nd Nov 20225:08 pmRNSHolding(s) in Company
19th Oct 202210:40 amRNSExercise of Share Options and Total Voting Rights
14th Oct 20223:12 pmRNSHolding(s) in Company
11th Oct 20221:40 pmRNSHolding(s) in Company
10th Oct 20222:06 pmRNSHolding(s) in Company
21st Sep 20224:18 pmRNSHolding(s) in Company
20th Sep 20222:02 pmRNSHolding(s) in Company
14th Sep 202211:56 amRNSResult of Annual General Meeting
14th Sep 20227:00 amRNSAGM Statement
2nd Sep 20229:41 amRNSHolding(s) in Company
30th Aug 20227:00 amRNSLaunch of Group 2022 SAYE Scheme
16th Aug 20223:38 pmRNSExercise of Share Options and Total Voting Rights
9th Aug 20227:00 amRNSPublication of Notice of AGM and Annual Report
8th Aug 20227:00 amRNSChange of Auditor
7th Jul 20225:14 pmRNSDirector/PDMR Shareholding
5th Jul 20222:24 pmRNSExercise of Share Options and Total Voting Rights
4th Jul 20223:54 pmRNSExercise of Share Options and Total Voting Rights
4th Jul 20222:10 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.